Australia's Starpharma hits 3-1/2-year high on FDA nod for cancer-treating therapy

Starpharma Holdings

21/04/2026 06:56

** Shares of Australia's Starpharma Holdings SPL.AX rise as much as 9.6% to A$0.745, highest point since August 24, 2022

** Biotech firm says it met with the U.S. Food and Drug Administration (US FDA), received positive feedback on its first-in-human (FIH) phase 1 clinical study of DEP HER2 radiotherapy candidate

** DEP HER2 is a radiotherapy that helps in the treatment of gastric cancers

** Stock up 97.2% YTD, including day's moves

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))